Exkivity, a treatment for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation, is being withdrawn from the market. The highly anticipated oral treatment failed to demonstrate efficacy in a confirmatory clinical trial, leading to its market withdrawal. With no competition, Rybrevant is expected to remain the market leader for the foreseeable future.

According to industry sources on April 4, Takeda withdrew the market approval for Exkivity as of the first of this month. Takeda’s Exkivity was approved in Korea in July 2022 to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation. H